Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Proteus Syndrome and Related Congenital Disorders
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), April 2008
Sponsored by: National Human Genome Research Institute (NHGRI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001403
  Purpose

This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty tissue or blood vessels, asymmetric arms or legs, and large feet with very thick soles. The study will explore the genetic and biochemical cause and course of the disease, the changes in symptoms over time, and the effects of the disease on patients.

Patients with Proteus syndrome and their parents may be eligible for this study. Parents will be studied, when possible, for comparison of molecular findings. Study candidates will have a medical history and physical examination, including X-rays and possibly other imaging tests, such as computerized tomography (CT), magnetic resonance imaging (MRI) and ultrasound. Other tests and examinations may be done if needed.

Those enrolled in the study will have will be interviewed or complete questionnaires, or both, about how their disease affects them. (Parents will be asked about their feelings about having a child with a rare disorder.) Patients will provide a small blood sample for research and may be asked to undergo biopsies from a normal area of skin and from a tumor.

...


Condition
Growth Disorder
Mental Retardation
Multiple Abnormalies

Genetics Home Reference related topics: Cowden syndrome
MedlinePlus related topics: Cancer Growth Disorders
U.S. FDA Resources
Study Type: Observational
Official Title: The Phenotype and Etiology of Proteus Syndrome

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1500
Study Start Date: April 1994
Detailed Description:

The purpose of this project is to determine the natural history and etiology of Proteus syndrome. The natural history and the phenotypic range will be determined by clinical assessment and longitudinal follow-up of a cohort of patients. Subjects will be screened for eligibility using published diagnostic criteria for Proteus syndrome. The determination of the molecular etiology of this disorder will be difficult. It is extremely rare, affected patients have a shortened lifespan, and the disorder is sporadic. Thus the typical approach of positional cloning is not useful. The etiology of this disorder will be studied using various comparative molecular biology techniques including cDNA arrays, genomic arrays, subtractive techniques, testing of candidate genes, and other appropriate techniques. We will also test for dysregulation of growth controlling hormones and binding proteins in vivo.

Note is made that although this protocol is currently structured to recruit only subjects with Proteus syndrome, it was previously used for a more general group of sporadic birth defect syndromes. The original goals for that group have been accomplished, which was the determination of the frequency of submicroscopic chromosomal rearrangements and uniparental disomy. That group of patients (and unaffected parents) is no longer being recruited but the specimens are retained. These specimens will be tested for appropriate candidate genes if, and when, that opportunity should arise.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

For Proteus Patients

All affected subjects should have the following general criteria: mosaic distribution of lesions, progressive course, and sporadic occurrence.

In addition, they should have either 1 from A, 2 from B or 3 from C.

A. Cerebriform connective tissue nevus.

B. Epidermal nevus, Disproportionate overgrowth, specific tumors before the age of 30 years (bilateral. ovarian cystadenomas or monomorphic parotid adenoma).

C. Dysregulated adipose tissue, Vascular malformations, Lung cysts, Facial phenotype.

The Proteus mail-in and Proteus case review subjects must meet the same eligibility standards as those who come to the clinical center and this will be determined by the review of the materials.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001403

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, District of Columbia
Childrens National Medical Center Recruiting
Washington, District of Columbia, United States
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 940132, 94-HG-0132
Study First Received: November 3, 1999
Last Updated: July 18, 2008
ClinicalTrials.gov Identifier: NCT00001403  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Mental Retardation
Growth Retardation
Uniparental Isodisomy
Imprinting
Multiple Abnormalities
Proteus Syndrome
Overgrowth

Study placed in the following topic categories:
Hamartoma Syndrome, Multiple
Proteus Syndrome
Proteus Infections
Bone Diseases
Musculoskeletal Abnormalities
Mental Retardation
Signs and Symptoms
Musculoskeletal Diseases
Mental Disorders
Growth Disorders
Mental Disorders Diagnosed in Childhood
Bone Diseases, Developmental
Abnormalities, Multiple
Neurologic Manifestations
Proteus syndrome
Congenital Abnormalities
Neurobehavioral Manifestations

Additional relevant MeSH terms:
Limb Deformities, Congenital
Neoplasms
Pathologic Processes
Disease
Syndrome
Neoplasms, Multiple Primary
Nervous System Diseases
Hamartoma

ClinicalTrials.gov processed this record on January 15, 2009